Current calls, week 12, 2024
Tips from KI Grants Office about current calls
Swedish and Nordic calls
Forskningsanslag - Svensk Reumatologisk Förening i samarbete med AstraZeneca
Anslaget stödjer experimentell eller klinisk forskning med fokus på SLE. Anslaget omfattar 100 000 kr och kan ej användas för resa, deltagande i kongress, egen utbildning eller för ordinarie klinisk verksamhet. Hela stipendiet utdelas som forskningsanslag och förvaltas av stipendiatens forskningsinstitution.
Closing date: April 18, 2024
Forskningsanslag - Svensk Reumatologisk Förening i samarbete med Boehringer-Ingelheim AB
Anslaget stödjer experimentell eller klinisk forskning med fokus på lungengagemang vid reumatisk sjukdom. Anslaget omfattar 100 000 kr och kan ej användas för resa, deltagande i kongress, egen utbildning eller för ordinarie klinisk verksamhet. Hela stipendiet utdelas som forskningsanslag och förvaltas av stipendiatens forskningsinstitution.
Closing date: April 18, 2024
Forskningsanslag - Svensk Reumatologisk Förening i samarbete med UCB Pharma Sweden
Anslaget stödjer forskning av reumatiska sjukdomar – artritsjukdomar, gärna med fokus på spondartriter, dvs experimentell eller klinisk sjukdomsorienterad forskning avseende reumatisk sjukdom och därtill relaterade följdsjukdomar. Anslaget omfattar 100 000 kr och kan inte användas för resa, deltagande i kongress, egen utbildning eller för ordinarie klinisk verksamhet. Hela stipendiet utdelas som forskningsanslag och förvaltas av stipendiatens forskningsinstitution.
Closing date: April 18, 2024
Forskningsanslag - Svensk Reumatologisk Förening i samarbete med Alfasigma
Anslaget stödjer experimentell eller klinisk forskning med fokus på artriter. Anslaget omfattar 100 000 kr och kan inte användas för resa, deltagande i kongress, egen utbildning eller för ordinarie klinisk verksamhet. Hela stipendiet utdelas som forskningsanslag och förvaltas av stipendiatens forskningsinstitution.
Closing date: April 18, 2024
Forskningsanslag - Svensk Reumatologisk Förening i samarbete med CSL Vifor
Anslaget stödjer forskning av reumatiska sjukdomar inom området ANCA-associerad vaskulit. Anslaget omfattar 100 000 kr och kan inte användas för resa, deltagande i kongress, egen utbildning eller för ordinarie klinisk verksamhet. Hela stipendiet utdelas som forskningsanslag och förvaltas av stipendiatens forskningsinstitution.
Closing date: April 18, 2024
Stipendium - Nationella Föreningen för Sjuksköterskor i Kirurgisk vård (NFSK)
NFSK inbjuder ansökningar om kirurgiskt omvårdnadsstipendium. Detta stöder specialistsjuksköterskor och studenter inom kirurgisk vård. Stipendiesumman ska användas till projekt, utbildning eller utveckling för patient och/eller personal på kliniken.
Closing date: May 19, 2024
Forskningsprojekt - Afa Försäkring
Afa Försäkring utlyser ett FoU-program om arbetsmiljön i den gröna omställningen. Med ny och användbar kunskap inom området ska programmet bidra till säkra och hälsosamma arbetsplatser under den pågående omvandlingen mot en mer miljövänlig och hållbar framtid. Syftet med programmet är att studera vilka konsekvenser den gröna omställningen ger upphov till i arbetsmiljön för både arbetare och tjänstemän i privat sektor, generera ny kunskap om den gröna omställningens konsekvenser för arbetsmiljön och bidra till lämpliga åtgärder för att skapa säkra och hälsosamma arbetsplatser. Programmet omfattar 40 miljoner kronor, startar i november 2024 och pågår i tre år.
Den 4 april kl. 13.00 –14.00 bjuder Afa Försäkring in till en informationsträff om FoU-programmet och utlysningen i Teams.
Closing date: June 3, 2024
Stipendier för forskning i Frankrike
Svensk-Franska Stiftelsen har sedan 1935 verkat för att främja kontakterna mellan Sverige och Frankrike genom att dela ut stipendier för eftergymnasiala studier och forskningsutbyte i Frankrike. Stiftelsens inriktning är bred och forskare från olika vetenskapliga inriktningar välkomnas. Stiftelsens stadgar stipulerar att man måste vara svensk medborgare för att kunna tilldelas medel.
Stiftelsen har de senaste åren delat ut ca 700-800 tkr per år. Det maximala beloppet per ansökan är 200 tkr.
Closing date: April 15, 2024
European calls
Core Facility Fellowships - European Molecular Biology Organisation (EMBO)
EMBO Core Facility Fellowships fund international exchanges of up to one month between core research facilities in eligible countries. Core Facility Fellowships are intended for the training of core facilities staff, including scientists and technicians, in specific techniques used in core research facilities that provide services to research institutions or universities. The fellowships contribute towards travel and subsistence of the fellow. The applicant must be an active research scientist or technician working in a core research facility with at least one year of laboratory experience. There is no age limit.
There is no deadline for applications, however it is recommended to apply three months before the proposed starting date. At minimum, applications must be submitted 30 days before the start date of the research visit.
Short clinical exchange programme - European AIDS Clinical Society
The short clinical exchange programme aims at promoting clinical, research and educational links between centres across Europe and facilitating exchange of models of clinical care in HIV medicine and allied specialities. Eligible candidates are physician/clinical scientists or allied health care specialists (Nurse, pharmacist, laboratory researcher, dietician, psychologist/counsellor) currently working in the field of HIV medicine/infectious diseases or genito-urinary medicine. Candidates must hold EACS membership, and be in a training post at the time of application.
Fellows will have the opportunity to visit an EACS Clinical/Research Excellence Center (CREC) specialised in HIV medicine for a period of 2 to 4 weeks.
Closing date: 29 April 2024
Advanced research grants in amyotrophic lateral sclerosis - Radala Foundation for ALS Research
The Radala Foundation invites applications for its advanced research grants in amyotrophic lateral sclerosis (ALS). These support potentially ground-breaking, high-risk projects in basic research in amyotrophic lateral sclerosis. Research must be conducted in a public or private research organisation. Established, leading PIs may apply. They are expected to be active researchers and have a track-record of significant research achievements in the last 10 years. These awards are not directed to clinically related projects for patient care. One or two grants of 200,000 Swiss francs will be given each year.
Deadline: 30 June 2024
International 3Rs prize - National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
Have you published a paper that describes outstanding and original work that has or could have major impacts on the replacement, reduction or refinement of the use of animals in research? If so, then you should apply for the annual NC3Rs prize which is co-funded by GSK to recognise a paper published in the last three years with demonstrable 3Rs impacts. This prestigious award consists of a £28k prize grant and a £2k personal award.
Closing date: 1 May 2024
Meeting support grants - European Federation of Immunological Societies (EFIS)
EFIS and the European Journal of Immunology (EJI) are proud to offer financial support for immunology-themed meetings, workshops and schools that are organized in Europe and are international in nature.
Specifically, through its support, EFIS aims to enhance interaction between early career scientists and established immunologists, providing funding to be used as travel bursaries to award to eligible and deserving junior researchers who, in many cases, would be unable to attend quality immunology-themed events without such support. Organizers should also bear in mind that EFIS-EJI Support must be used to subsidize early career researchers' participation costs and cannot be used to directly finance an event.
Closing date: 3 May 2024
US calls
Federal Funding
Notice of Special Interest (NOSI): U.S. Health in the International Perspective
Funding Opportunity ID: NOT-AG-24-004
Upcoming deadlines: Standard dates apply until May 08, 2027.
Abstract: This NOSI expresses NIA’s interest in research that examines mechanisms and causes behind the increasing U.S. health disadvantage, which refers to worsening life expectancies and health outcomes in the U.S. compared to other countries. Of particular interest are projects that examine cross-national and U.S. cross-regional or cross-state differences in policy context that may drive poor health outcomes.
Notice of Special Interest (NOSI): Priority Research Opportunities in Crisis Response Services
Funding Opportunity ID: NOT-MH-22-110
Upcoming deadlines: Standard dates apply until May 08, 2025.
Abstract: The National Action Alliance for Suicide Prevention's (Action Alliance) Crisis Services Task Force summarized needed crisis services for suicide prevention in their 2016 report, Crisis Now: Transforming Services is Within Our Reach. The report describes effective crisis care as a systematic approach, optimized when delivered with the following characteristics: Regional or statewide crisis call centers that use technology to support real-time coordination across a system of care; centrally deployed mobile crisis outreach and support on a 24/7 basis; and crisis services that can diagnose and provide short term stabilization. In addition to their therapeutic value for the individual in crisis, effective crisis systems that support individuals in suicide distress have been reported to be successful diversions from law enforcement by supporting emergency care that reduces avoidable hospital admissions, arrest, and incarceration.
Notice of Special Interest (NOSI): Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology
Funding Opportunity ID: NOT-CA-23-060
Upcoming deadlines: Standard dates apply until 08 January 2026.
Abstract: Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype.
More info: NOT-CA-23-060: Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology (nih.gov)
Notice of Intent to Publish a Funding Opportunity Announcement for The Road to Prevention of Stillbirth (UM2 Clinical Trial Not Allowed)
Funding Opportunity ID: NOT-HD-24-009
Upcoming deadlines: November 01, 2024 (estimated).
Abstract: The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for a Data Coordinating Center to support the work of the research projects funded under the Stillbirth Research Consortium described in the companion announcement NOT-HD-24-009.
This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and prepare responsive applications.
The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024.
Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed)
Funding Opportunity ID: RFA-AG-25-017
Upcoming deadlines: June 10, 2024
Abstract: This notice of funding opportunity (NOFO) invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. NIA encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD).
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 and R21 Clinical Trial Not Allowed)
Funding Opportunity ID: RFA-DA-25-004 (R01); RFA-DA-25-005 (R21).
Upcoming deadlines: November 13, 2024
Abstract: The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our knowledge of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity.
Applications testing a fully conceptualized premise founded with adequate preliminary data are appropriate for this NOFO.
Exploratory research projects should consider applying to the companion R21 announcement RFA-DA-25-005.
More info: RFA-DA-25-004: Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed) (nih.gov); RFA-DA-25-005: Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed) (nih.gov)
Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
Funding Opportunity ID: PAR-23-239
Upcoming deadlines: Standard dates apply until September 08, 2026
Abstract: The purpose of this Notice of Funding Opportunity (NOFO) is to encourage research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental.
This NOFO solicits R21 applications, while the companion announcement PAR-23-238 solicits R01 applications. High risk/high payoff projects that lack preliminary data may be most appropriate for this R21 mechanism, while applications with preliminary data should apply to the R01 mechanism, PAR-23-238.
Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required
Funding Opportunity ID: RFA-FD-23-001
Upcoming deadlines: October 22, 2024
Abstract: The purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.
Foundation
Society for Academic Emergency Medicine Foundation (SAEMF), US - SAEMF Emerging Infectious Disease and Preparedness Grant
Upcoming deadlines: 1st August, 2024
Amount: $100,000 USD
Eligibility: Be a member of SAEM in good standing at application deadline and during the entire award period. Have an advanced/doctoral or terminal educational degree (e.g., MD, DO, PhD, PharmD, DSc or equivalent). Hold a university appointment in or be actively involved (e.g., have an adjunct appointment) with a department or division of emergency medicine or pediatric emergency medicine at the start of award period.
Abstract: The Emerging Infectious Disease and Preparedness Grant provides up to $100,000 over a one-year period starting July 1 to support emergency care research related to emerging infectious disease, such as influenza, COVID-19, and other bacterial or viral infections. This award is not limited to specific conditions and may study an infectious disease at any point in its epidemiologic trajectory. This award seeks to support an ambitious program of acute care science in emerging infectious disease that may include:
- Diagnostics
- Patient and provider safety
- Intervention/therapeutics
- Disaster preparedness
- Other relevant topic areas
Website: SAEMF Emerging Infectious Disease and Preparedness Grant
Amyotrophic Lateral Sclerosis Association, US – Seeds Grants
Upcoming deadlines: LOI – 9th April 2024; Full application - 20th June, 2024
Amount: $50,000 in total funding over 1 year
Eligibility: Seed Grants are open to individuals worldwide who have the skills, knowledge and resources necessary to carry out the proposed project. Since impactful ideas can come from anywhere, applicants do not need to have a scientific background in ALS research. Established investigators, early career investigators and investigators from outside the ALS field are all encouraged to apply.
Abstract: Seed Grants provide initial support for projects from across the spectrum of ALS research. These awards were designed to fund one or two critical experiments intended to gather preliminary data that will serve as the basis for larger grants. As such, Seed Grant applicants do not need to have preliminary data in hand but should instead demonstrate a comprehensive understanding of both why the experiments proposed for funding are the key experiments in the short term and how the results can be leveraged to secure follow-on funding in the longer term.
Applications from early career investigators in ALS and investigators from outside the field of ALS are encouraged.
Website: Seed Grants | The ALS Association
Amyotrophic Lateral Sclerosis Association, US – Seed Grants
Upcoming deadlines: LOI – 9th April, 2024; Full application – 20th June, 2024
Amount: $50,000 in total funding over 1 year to conduct preliminary ALS research that will support funding applications from other sources for larger scale and more impactful research projects.
Eligibility: Senior postdoctoral fellows, defined as fellows who have been in their current postdoctoral position for at least 3 years on the date full proposals are due, may apply as a PI.
Established investigators, early career investigators, and investigators from outside the ALS field are all eligible to apply as a PI.
Abstract: Seed Grants provide initial support for projects from across the spectrum of ALS research. These awards were designed to fund one or two critical experiments intended to gather preliminary data that will serve as the basis for larger grants. As such, Seed Grant applicants do not need to have preliminary data in hand but should instead demonstrate a comprehensive understanding of both why the experiments proposed for funding are the key experiments in the short term and how the results can be leveraged to secure follow-on funding in the longer term. Applications from early career investigators in ALS and investigators from outside the field of ALS are encouraged.